These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
269 related articles for article (PubMed ID: 16638345)
1. [Prediction of the stage of patients with prostate cancer by the combination of serum prostate specific antigen and Gleason score]. Song G; Zhou LQ; He ZS; Li NC; Li M; Hao JR; Pan BN; Na YQ Zhonghua Wai Ke Za Zhi; 2006 Mar; 44(6):376-8. PubMed ID: 16638345 [TBL] [Abstract][Full Text] [Related]
2. Serum insulin level, disease stage, prostate specific antigen (PSA) and Gleason score in prostate cancer. Lehrer S; Diamond EJ; Stagger S; Stone NN; Stock RG Br J Cancer; 2002 Sep; 87(7):726-8. PubMed ID: 12232754 [TBL] [Abstract][Full Text] [Related]
3. [Total PSA, PSA density and biopsy Gleason score in predicting the pathologic stage of prostate cancer]. Liu S; Lü JJ; Fu Q; Zhang H; Gao DX; Liu Z Zhonghua Nan Ke Xue; 2010 May; 16(5):415-9. PubMed ID: 20684321 [TBL] [Abstract][Full Text] [Related]
4. Electrophoretic subforms of free prostate-specific antigen in serum as promising diagnostic tool in prostate cancer diagnostics. Jung K; Hoesel W; Reiche J; Deger S; Kramer J; Loening SA; Lein M; Stephan C Urology; 2007 Feb; 69(2):320-5. PubMed ID: 17320672 [TBL] [Abstract][Full Text] [Related]
5. Comparison of predictive accuracy for pathologically organ confined clinical stage T1c prostate cancer using human glandular kallikrein 2 and prostate specific antigen combined with clinical stage and Gleason grade. Haese A; Vaisanen V; Lilja H; Kattan MW; Rittenhouse HG; Pettersson K; Chan DW; Huland H; Sokoll LJ; Partin AW J Urol; 2005 Mar; 173(3):752-6. PubMed ID: 15711262 [TBL] [Abstract][Full Text] [Related]
6. Serum human glandular kallikrein 2 (hK2) for distinguishing stage and grade of prostate cancer. Stephan C; Jung K; Nakamura T; Yousef GM; Kristiansen G; Diamandis EP Int J Urol; 2006 Mar; 13(3):238-43. PubMed ID: 16643616 [TBL] [Abstract][Full Text] [Related]
7. [The usefulness of percentage of free prostate specific antigen/prostate specific antigen density in the diagnosis of prostate cancer]. Han G; Gao JP; Cao XL; Hong BF; Tang J Zhonghua Wai Ke Za Zhi; 2006 Mar; 44(6):379-81. PubMed ID: 16638346 [TBL] [Abstract][Full Text] [Related]
8. Free-to-total prostate specific antigen ratio as a single test for detection of significant stage T1c prostate cancer. Elgamal AA; Cornillie FJ; Van Poppel HP; Van de Voorde WM; McCabe R; Baert LV J Urol; 1996 Sep; 156(3):1042-7; discussion 1047-9. PubMed ID: 8709304 [TBL] [Abstract][Full Text] [Related]
9. Multigene methylation analysis for detection and staging of prostate cancer. Enokida H; Shiina H; Urakami S; Igawa M; Ogishima T; Li LC; Kawahara M; Nakagawa M; Kane CJ; Carroll PR; Dahiya R Clin Cancer Res; 2005 Sep; 11(18):6582-8. PubMed ID: 16166436 [TBL] [Abstract][Full Text] [Related]
10. An artificial neural network for prostate cancer staging when serum prostate specific antigen is 10 ng./ml. or less. Zlotta AR; Remzi M; Snow PB; Schulman CC; Marberger M; Djavan B J Urol; 2003 May; 169(5):1724-8. PubMed ID: 12686818 [TBL] [Abstract][Full Text] [Related]
11. Percent free PSA as an additional measure in a prostate cancer screen. Miele ME Clin Lab Sci; 2001; 14(2):102-7. PubMed ID: 15625982 [TBL] [Abstract][Full Text] [Related]
12. Free-to-total prostate specific antigen ratio in clinical staging of prostate cancer. Maeda H; Arai Y; Ishitoya S; Okubo K; Aoki Y; Okada T; Maekawa S Hinyokika Kiyo; 1998 May; 44(5):307-11. PubMed ID: 9656100 [TBL] [Abstract][Full Text] [Related]
13. [The relationships of PSA, FPSAR, clinical and pathological stage in patients with prostate cancer]. Liu HL; Wang H; Yang XJ; Chen BQ; Qin RL; Shao GX Zhonghua Nan Ke Xue; 2002; 8(4):261-3. PubMed ID: 12491689 [TBL] [Abstract][Full Text] [Related]
14. Is prostate-specific antigen (PSA) density better than the preoperative PSA level in predicting early biochemical recurrence of prostate cancer after radical prostatectomy? Jones TD; Koch MO; Bunde PJ; Cheng L BJU Int; 2006 Mar; 97(3):480-4. PubMed ID: 16469012 [TBL] [Abstract][Full Text] [Related]
15. Evaluation of proprostate specific antigen for early detection of prostate cancer in men with a total prostate specific antigen range of 4.0 to 10.0 ng/ml. Khan MA; Partin AW; Rittenhouse HG; Mikolajczyk SD; Sokoll LJ; Chan DW; Veltri RW J Urol; 2003 Sep; 170(3):723-6. PubMed ID: 12913682 [TBL] [Abstract][Full Text] [Related]
16. Comparison of several combinations of free, complexed, and total PSA in the diagnosis of prostate cancer in patients with urologic symptoms. Filella X; Truan D; Alcover J; Quintó L; Molina R; Luque P; Coca F; Ballesta AM Urology; 2004 Jun; 63(6):1100-3; discussion 1103-4. PubMed ID: 15183958 [TBL] [Abstract][Full Text] [Related]
17. A multicenter clinical trial on the use of alpha1-antichymotrypsin-prostate-specific antigen in prostate cancer diagnosis. Lein M; Jung K; Hammerer P; Graefen M; Semjonow A; Stieber P; Ossendorf M; Luboldt HJ; Brux B; Stephan C; Schnorr D; Loening SA Prostate; 2001 May; 47(2):77-84. PubMed ID: 11340629 [TBL] [Abstract][Full Text] [Related]
18. Ratio of free-to-total prostate specific antigen correlates with tumor volume in patients with increased prostate specific antigen. Grossklaus DJ; Shappell SB; Gautam S; Smith JA; Cookson MS J Urol; 2001 Feb; 165(2):455-8. PubMed ID: 11176395 [TBL] [Abstract][Full Text] [Related]
19. [Evaluation for clinical staging parameters of prostate neoplasm]. Zhong CY; Liu M; Zhang LQ; Wan B Zhonghua Nan Ke Xue; 2003 Apr; 9(2):100-2. PubMed ID: 12749126 [TBL] [Abstract][Full Text] [Related]
20. Prostate biopsy clinical and pathological variables that predict significant grading changes in patients with intermediate and high grade prostate cancer. Moussa AS; Li J; Soriano M; Klein EA; Dong F; Jones JS BJU Int; 2009 Jan; 103(1):43-8. PubMed ID: 18782303 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]